Ceritinib

證據等級: L5

預測適應症: 10 個

Ceritinib: From ALK-Positive NSCLC to Fibromatosis, Gingival

One-Sentence Summary

Ceritinib is a second-generation ALK tyrosine kinase inhibitor whose established use — based on the literature in this evidence pack — is ALK-positive non-small-cell lung cancer (NSCLC). The TxGNN model's top-ranked prediction is Fibromatosis, Gingival, with a raw score of 99.86%, but this is currently supported by 0 clinical trials and 0 publications — the model's own rationale flags it as likely embedding-space noise rather than a genuine mechanistic signal.

Quick Overview

Item	Content
Original Indication	Not available in Germany regulatory data (drug not marketed, 0 licenses); per literature evidence in this pack, ceritinib was developed for ALK-positive non-small cell lung cancer (NSCLC)
Predicted New Indication	Fibromatosis, Gingival
TxGNN Prediction Score	99.86%
Evidence Level	L5 (model prediction only, no clinical trial or literature support)
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for ceritinib is not available (flagged as a High-severity data gap in this evidence pack). Based on the literature evidence attached to lower-ranked predictions in this pack, ceritinib is known to be an oral, potent ALK (anaplastic lymphoma kinase) inhibitor, and its efficacy in ALK-rearranged NSCLC has been established by Phase 3 randomised evidence (e.g., ASCEND-4). Mechanistically, ALK inhibitors would be expected to have therapeutic relevance only in diseases with a demonstrated ALK-driven pathology (e.g., ALK+ NSCLC, ALK-mutated neuroblastoma, anaplastic large cell lymphoma).

For the top-ranked candidate in this pack, Fibromatosis, Gingival, no such ALK-driven pathology has been reported in the literature. The evidence pack's own repurposing rationale states this explicitly: "牙齦纖維瘤病無已知 ALK 通路涉入之報導，TxGNN 高分推測為 embedding 空間鄰近雜訊，無機轉支持" (gingival fibromatosis has no known ALK pathway involvement; the high TxGNN score is likely attributable to embedding-space proximity noise, not mechanistic support). This is corroborated by the complete absence of clinical trial and literature evidence (0/0) for this specific indication.

It is worth noting that within the same evidence pack, other lower-ranked predictions (e.g., rank 5 "lung benign neoplasm," rank 7 "lung germ cell tumor") carry substantially richer literature bodies — though these too show disease-label/evidence mismatches, since the attached studies concern ALK+ malignant NSCLC and ALK-driven neuroblastoma rather than the benign/germ-cell entities nominally predicted. None of the top-10 predictions in this pack currently have evidence that directly and specifically supports the labeled indication.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Germany Market Information

Ceritinib is currently not marketed in Germany (market status: 未上市) with 0 registered authorizations. No license records are available to extract product name, dosage form, or approved indication text.

Cytotoxicity

Ceritinib is an antineoplastic agent (ALK tyrosine kinase inhibitor; per literature in this pack, developed for and studied in ALK-positive NSCLC).

Item	Content
Cytotoxicity Classification	Targeted therapy (ALK tyrosine kinase inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Not specified in this evidence pack; as a targeted small-molecule TKI, myelosuppression is generally expected to be lower than with conventional cytotoxic chemotherapy — please refer to the package insert
Emetogenicity Classification	Low to moderate — GI toxicity (nausea, vomiting, diarrhea) is a recognised class effect referenced in the literature (e.g., ASCEND-8 food-effect subgroup analysis)
Monitoring Items	Liver function tests (hepatotoxicity), QT interval/ECG (QT prolongation reported as a class effect for ALK TKIs including ceritinib), blood glucose, CBC
Handling Protection	Oral targeted therapy — hazardous drug handling precautions per institutional oncology pharmacy protocol are still advised, though generally less stringent than IV cytotoxic chemotherapy handling requirements

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all marked as data gaps in this evidence pack; TFDA/BfArM package insert data is flagged as a Blocking-severity gap that prevents entry into S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication (Fibromatosis, Gingival) has zero supporting clinical trials or literature, and the evidence pack's own mechanistic rationale identifies the high TxGNN score as likely computational noise rather than a genuine biological signal. Combined with the Blocking-severity data gap on safety/warnings, this candidate cannot proceed past S0.

To proceed, the following is needed:

TFDA/BfArM package insert data (warnings, contraindications) — currently a Blocking data gap
DrugBank-sourced mechanism of action (MOA) data — currently a High-severity gap
If repurposing exploration continues for this drug, prioritize re-scoring or manual curation of lower-ranked candidates with richer but currently mismatched evidence (e.g., rank 7 "lung germ cell tumor," where literature actually concerns ALK-driven neuroblastoma and a completed CNS-penetration trial) rather than the rank-1 candidate presented here
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.